Brown Brothers Harriman & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brown Brothers Harriman & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-225	Closed	-$25.6K	–	1354
2022 Q4	$25.6K	Hold	225	–	–	﹤0.01%	830
2022 Q3	$14K	Sell	225 -23	-9%	-$1.61K	﹤0.01%	1083
2022 Q2	$20K	Buy	248 +225	+978%	+$21.3K	﹤0.01%	884
2022 Q1	$2K	Hold	23	–	–	﹤0.01%	1208
2021 Q4	$2	Hold	23	–	–	﹤0.01%	1102
2021 Q3	$3	Hold	23	–	–	﹤0.01%	1056
2021 Q2	$2	Hold	23	–	–	﹤0.01%	1094
2021 Q1	$2	Hold	23	–	–	﹤0.01%	1047
2020 Q4	$2K	Buy	+23	New	+$1.71K	﹤0.01%	1040

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brown Brothers Harriman & Co's HZNP Position: Q1 2023 in Review

Brown Brothers Harriman & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 225 shares — an estimated $25.6K sold.

Brown Brothers Harriman & Co first reported a position in HZNP in Q4 2020 and held it in 9 quarters. The position peaked at $25.6K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Brown Brothers Harriman & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Brown Brothers Harriman & Co sold 225 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $25.6K.
Brown Brothers Harriman & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 9 quarters.
Brown Brothers Harriman & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $25.6K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2023, filed 11 May 2023.